SEC Form 4 · accession 0001628280-18-000655
Fibrocell Science, Inc. · FCSC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Michael Maslowski
Officer — CEO · Director
Period of report
Jan 25, 2018
Accepted (ET)
Jan 29, 2018 · 1:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000357097
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF2,F1 | $0.69 | Jan 25, 2018 | A | 100,000 | A | — | Jan 25, 2028 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1The options set forth in this table vest as follows: (i) 25,000 shares on January 25, 2019 and (ii) 6,250 shares for each of twelve quarterly installments beginning on April 25, 2019 and ending on January 25, 2022 provided the reporting person is employed by the Company on each vesting date.
- F2The options were issued in connection with the reporting person's employment service to the Company.